| Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions -> Monitor Keywords |
|
|
 
Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditionsRelated Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Inorganic Active Ingredient Containing, Heavy Metal Or Compound ThereofCombination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20060275503, Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions. Brief Patent Description - Full Patent Description - Patent Application Claims
FIELD OF THE INVENTION [0001] The present application relates to a combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions. BACKGROUND OF THE INVENTION [0002] Osteoporosis is the most common form of metabolic bone disease in humans. It is a condition, which affects a very large number of people all over the world, and as the number of elderly people is set to rise dramatically in the coming decades in most countries, the prevalence and impact of osteoporosis will also increase. The disease is characterized pathologically by an absolute decrease in the amount of bone mass and the structural quality of bone, and clinically by increased susceptibility to fractures. In fact, osteoporosis is the most significant underlying cause of skeletal fractures in late middle age and elderly women. [0003] In general, there are two types of osteoporosis: primary and secondary. Secondary osteoporosis is the result of an identifiable disease process or agent. However, approximately 90% of all osteoporosis cases are idiopathic primary osteoporosis. Such primary osteoporosis includes postmenopausal osteoporosis, age-associated osteoporosis (affecting a majority of individuals over the age of 70 to 80), and idiopathic osteoporosis affecting middle-aged and younger men and women. [0004] The mechanism of bone loss in osteoporosis is believed to involve an imbalance in the process of bone remodeling. Bone remodeling occurs throughout life, renewing the skeleton and maintaining the strength of bone. This remodeling is mediated by specialized cells within the bone tissue, called "osteoclasts" and "osteoblasts". Osteoclasts (bone dissolving or resorbing cells) are responsible for the resorption of a portion of bone within the bone matrix, during the resorption process. After resorption, the osteoclasts are followed by the appearance of osteoblasts (bone forming cells), which then refill the resorbed portion with new bone. [0005] The formation of the two cell types as well as their activity in bone is usually tightly coupled and well regulated in order to maintain the skeletal balance and structural integrity of the bones. However, in people with osteoporosis an imbalance in this remodeling process develops, resulting in loss of bone at a rate faster than the accretion of bone. [0006] The single most important risk factor for osteoporosis is oestrogen deficiency occurring naturally at the menopause. The decline in endogenous oestrogen production leads to an elevated metabolic activity in the bone tissue where the increase in osteoclast mediated bone resorption surpasses the more modest increase in bone formation, resulting in a net loss of bone. The actual number of people affected will grow at a rate greater than simple population growth rates, because the aging of the population is disproportionately increasing the older segment of the population, while the age for the onset of menopause has remained constant. In the last decades there has also been a substantial advance in the ability to predict and monitor osteoporosis, as methods for measurement of bone mineral density (BMD) has improved and new specific biochemical markers of bone resorption and formation has been developed and made available for routine clinical use. New pharmaceutical agents for treatment and/or prevention of osteoporosis have also been developed. The majority of these treatments are based on substituting the lost endogenous estrogen either in the form of hormone replacement therapy (HRT) or selective estrogen receptor modulators (SERM), or they belong to the class of compounds called bisphosphonates. SERM's and especially HRT is associated with significant side effects, such as increased risk of cancer and cardiovascular disease, whereas bisphosphonates in addition to a potent antiresorptive effect also decreases bone formation to a similar extent, implying that they loose their therapeutic effect after few years of treatment. Thus, there is a need for agents, which are effective in the treatment and/or prophylaxis of osteoporosis. SUMMARY OF THE INVENTION [0007] In one aspect, the invention relates to a method for the treatment and/or prophylaxis of a cartilage and/or bone disease and/or conditions resulting in a dysregulation of cartilage and/or bone metabolism in a mammal, such as, e.g., a human female or male adult, adolescent or a child, such as, e.g., osteoporosis, osteoarthritis, osteopetrosis, osteopenia and Paget's disease, hypercalcemia of malignancy, periodontal disease, hyperparathyroidism, periarticular erosions in rheumatoid arthritis, osteodystrophy, myositis ossificans, Bechterew's disease, malignant hypercalcemia, osteolytic lesions produced by bone metastasis, bone pain due to bone metastasis, bone loss due to sex steroid hormone deficiency, bone abnormalities due to steroid hormone treatment, bone abnormalities caused by cancer therapeutics, osteomalacia, Bechet's disease, hyperostosis, metastatic bone disease, immobilization-induced osteopenia or osteoporosis, or glucocorticoid-induced osteopenia or osteoporosis, osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, for the improvement of fracture healing after traumatic or atraumatic fracture, and for the maintenance or increase of energy level, for building up or strengthening muscle tissues and for weight gain, the method comprising administering to a subject in need thereof a) a strontium-containing compound and b) one or more further active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone. [0008] In one embodiment of the method, the strontium-containing compound and one or more further active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone are administered in amounts that render the combination of the two effective in treating a cartilage and/or bone disease. [0009] In certain embodiments of the method, the administration of a) the strontium-containing compound and b) one or more further active substances leads to at least one of the following: [0010] i) improvement of bioavailability of a) and/or b) compared with administration of a) alone or b) alone in the same doses, [0011] ii) improvement of pharmacokinetic parameters of a) and/or b) compared with administration of a) alone or b) alone in the same doses, [0012] iii) reduction of frequency and/or magnitude of side-effects of a) and/or b) compared with administration of a) alone or b) alone in the same doses, [0013] iv) obtaining an additive or synergistic effect of a) and b) compared with administration of a) alone or b) alone in the same doses, [0014] v) reduction of the recommended daily dose (RDD) of a) and/or b) compared with RDD for a) alone or b) alone in the same doses to obtain a prophylactic and/or therapeutic effect. [0015] In some embodiments of the method, the administration of a) and b) in combination leads to an improvement of bioavailability of a) and/or b) of 10% or more, such as, 15% or more, 20% or more, 25% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more or 80% or more, compared with administration of a) alone or b) alone in the same doses. [0016] In certain embodiments of the method, the administration of a) and b) in combination leads to an improvement in at least one parameter selected from the group consisting of absorption rate, time to reach peak concentration (T.sub.max), peak concentration (C.sub.max), concentration vs. time curve, distribution volume or distribution to specific tissues, rate of metabolism, elimination rate and excretion rate. [0017] In some embodiments of the method, the administration of a) and b) in combination leads to a reduction of the daily dose of a) and/or b) needed to obtain a therapeutic or prophylactic effect as compared with the daily dose of a) or b) alone needed to obtain the same or almost same effect. For instance, in specific embodiments, the amount of a) and/or b) administered in combination is reduced by 10% or more, such as 15% or more, 20% or more, 25% or more, 30% or more, 40% or more, 50% or more, 60% or more or 75% or more. [0018] In certain embodiments of the method, the administration of a) and b) in combination leads to a reduction in side-effects. [0019] In some embodiments of the method, a) and b) are administered as a single composition. In other embodiments of the method, a) and b) are administered as separate compositions. [0020] In certain embodiments of the method, the administration of a) and b) takes place simultaneously or sequentially. [0021] In some embodiments of the method, the strontium-containing compound is selected from the group consisting of strontium salts of an organic or an inorganic acid. For example, in certain embodiments, the inorganic acid is selected from the group consisting of hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, phosphoric acid, phosphinic acid, phosphonic acid, sulfonic acid, sulfuric acid, sulfurous acid, disulfuric acid carbonic acid and boric acid. If a strontium salt of an organic acid is used, the organic acid is selected from the group consisting of acetic acid, C.sub.2H.sub.5COOH, C.sub.3H.sub.7COOH, C.sub.4H.sub.9COOH, (COOH).sub.2, CH.sub.2(COOH).sub.2, C.sub.2H.sub.4(COOH).sub.2, C.sub.3H.sub.6(COOH).sub.2, C.sub.4H.sub.8(COOH).sub.2, C.sub.5H.sub.10(COOH).sub.2, fumaric acid, maleic acid, malonic acid, lactic acid, citric acid, tartaric acid, oxalic acid, ascorbic acid, benzoic acid, salicylic acid, phthalic acid, pyruvic acid, L-aspartic acid, D-aspartic acid, carbonic acid, formic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, glucosamine sulphate, L-threonic acid, camphoric acid, gluconic acid, L-glutamic acid, D-glutamic acid, trifluoroacetic acid and ranelic acid. Continue reading about Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions... Full patent description for Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions or other areas of interest. ### Previous Patent Application: System for preparing oxygenated water with a stable negative oxidation reduction potential (orp) Next Patent Application: Methods and compositions for augmenting cancer chemotherapeutic agents Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions patent info. IP-related news and info Results in 0.53482 seconds Other interesting Feshpatents.com categories: Tyco , Unilever , Warner-lambert , 3m 174 |
 * Protect your Inventions * US Patent Office filing 
PATENT INFO |
|
